Brokerages Anticipate Alpine Immune Sciences Inc (ALPN) Will Post Quarterly Sales of $310,000.00

0
4


Wall Street brokerages forecast that Alpine Immune Sciences Inc (NASDAQ:ALPN) will announce $310,000.00 in sales for the current quarter, according to Zacks. Two analysts have provided estimates for Alpine Immune Sciences’ earnings, with the lowest sales estimate coming in at $300,000.00 and the highest estimate coming in at $320,000.00. Alpine Immune Sciences posted sales of $130,000.00 during the same quarter last year, which suggests a positive year-over-year growth rate of 138.5%. The business is scheduled to announce its next earnings report on Wednesday, March 27th.

According to Zacks, analysts expect that Alpine Immune Sciences will report full year sales of $860,000.00 for the current fiscal year, with estimates ranging from $710,000.00 to $1.02 million. For the next financial year, analysts anticipate that the company will post sales of $1.13 million, with estimates ranging from $1.00 million to $1.26 million. Zacks’ sales calculations are a mean average based on a survey of analysts that that provide coverage for Alpine Immune Sciences.

Alpine Immune Sciences (NASDAQ:ALPN) last issued its quarterly earnings results on Thursday, November 8th. The biotechnology company reported ($0.88) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.31). Alpine Immune Sciences had a negative return on equity of 43.25% and a negative net margin of 1,602.19%.

A number of analysts recently issued reports on ALPN shares. Zacks Investment Research downgraded Alpine Immune Sciences from a “hold” rating to a “sell” rating in a research report on Friday, January 11th. ValuEngine downgraded Alpine Immune Sciences from a “hold” rating to a “sell” rating in a research report on Friday, January 11th. Finally, Oppenheimer set a $13.00 price target on Alpine Immune Sciences and gave the stock a “buy” rating in a research report on Monday, November 12th. One equities research analyst has rated the stock with a sell rating and six have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $11.83.

In other Alpine Immune Sciences news, insider Mitchell Gold bought 190,875 shares of Alpine Immune Sciences stock in a transaction on Friday, January 18th. The shares were acquired at an average price of $5.37 per share, for a total transaction of $1,024,998.75. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director James N. Topper bought 372,439 shares of Alpine Immune Sciences stock in a transaction on Friday, January 18th. The stock was acquired at an average price of $5.37 per share, for a total transaction of $1,999,997.43. The disclosure for this purchase can be found here. Company insiders own 69.00% of the company’s stock.

A number of hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc increased its stake in Alpine Immune Sciences by 5.2% in the third quarter. Vanguard Group Inc now owns 227,834 shares of the biotechnology company’s stock worth $1,442,000 after purchasing an additional 11,200 shares during the period. Vanguard Group Inc. increased its stake in Alpine Immune Sciences by 5.2% in the third quarter. Vanguard Group Inc. now owns 227,834 shares of the biotechnology company’s stock worth $1,442,000 after purchasing an additional 11,200 shares during the period. Dimensional Fund Advisors LP increased its stake in Alpine Immune Sciences by 122.2% in the second quarter. Dimensional Fund Advisors LP now owns 32,819 shares of the biotechnology company’s stock worth $248,000 after purchasing an additional 18,052 shares during the period. Renaissance Technologies LLC increased its stake in Alpine Immune Sciences by 20.9% in the second quarter. Renaissance Technologies LLC now owns 122,424 shares of the biotechnology company’s stock worth $927,000 after purchasing an additional 21,124 shares during the period. Finally, Victory Capital Management Inc. increased its stake in Alpine Immune Sciences by 109.0% in the fourth quarter. Victory Capital Management Inc. now owns 136,072 shares of the biotechnology company’s stock worth $501,000 after purchasing an additional 70,980 shares during the period. Institutional investors and hedge funds own 55.63% of the company’s stock.

ALPN traded down $0.98 during trading on Thursday, reaching $5.50. The company had a trading volume of 64,550 shares, compared to its average volume of 15,320. Alpine Immune Sciences has a 52 week low of $3.66 and a 52 week high of $10.57. The company has a debt-to-equity ratio of 0.05, a quick ratio of 9.20 and a current ratio of 9.20.

About Alpine Immune Sciences

Alpine Immune Sciences, Inc focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, inflammatory disorders, and other diseases. Its lead programs include ALPN-101, an ICOS/CD28 antagonist program for the treatment of autoimmune and inflammatory diseases; and ALPN-202 program for the treatment of cancer.

Recommended Story: What are trading strategies for the 52-week high/low?

Get a free copy of the Zacks research report on Alpine Immune Sciences (ALPN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Alpine Immune Sciences Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Alpine Immune Sciences and related companies with MarketBeat.com’s FREE daily email newsletter.



Source link

LEAVE A REPLY

Please enter your comment!
Please enter your name here